Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 1

Status

Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 93INDUSTRY 33NIH 6NETWORK 3FED 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3Neoplasm Metastasis 2Parkinson Disease 4, Autosomal Dominant Lewy Body 1

Interventions

pembrolizumab 3enzalutamide 3Abiraterone Acetate 3apalutamide 2Topotecan 2Testosterone 2Itraconazole 2Docetaxel 2Cholecalciferol 2Celecoxib 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2zanubrutinib 1venetoclax 1talabostat 1sargramostim 1pasireotide 1olaparib 1leucoselect phytosome 1ibrutinib 1capivasertib 1acalabrutinib 1abiraterone 1Tablets 1Streptozocin 1Rituximab 1Radiosurgery 1Pluvicto 1PT-100 dipeptide 1Oxaliplatin 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × FED × enzalutamide × Clear all
NCT04116775 2022-06-23

Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.

Portland VA Medical Center

Phase 2 Unknown
32 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT05422911 2022-06-21

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

James J. Peters Veterans Affairs Medical Center

Phase 2 Not yet recruiting
200 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT03753243 2022-04-20

Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

Portland VA Medical Center

Phase 2 Recruiting
32 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡